Back

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Chronic heart failure – Treatment Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

8 More presentations in this session

Presentation thumbnail
Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant
Doctor I. Hernandez Gonzalez (Valladolid, ES)
Abstract
Presentation thumbnail
Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support
Doctor T. Ichiki (Rochester, US)
Abstract
Presentation thumbnail
Identification of patients eligible to start sacubitril valsartan in a stable heart failure population
Doctor S. Aktaa (Leeds, GB)
Abstract Slides
Presentation thumbnail
What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels
Doctor P. Pellicori (Glasgow, GB)
Abstract
Presentation thumbnail
Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction
Doctor M. Li (Osaka, JP)
Abstract

Access the full session

Session thumbnail
Poster Session 7 - Chronic heart failure – Treatment

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources